Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics’ 10-Ks read like molecular biology textbooks. Investors hunting for how degrader programs move from lab to clinic or when a strategic collaboration alters cash burn often wade through hundreds of pages. Add Form 4 disclosures about scientists exercising options, and the picture gets even more intricate.
Stock Titan turns those challenges into clarity. Our AI-powered summaries deliver “C4 Therapeutics SEC filings explained simply,” mapping each disclosure to what matters: pipeline milestones, royalty obligations, and trial funding. Whether you need the “C4 Therapeutics quarterly earnings report 10-Q filing” or an “8-K material events explained” after a pivotal data release, every document arrives in real time, complete with plain-English context.
- Form 4 alerts flag “C4 Therapeutics insider trading Form 4 transactions” and “C4 Therapeutics executive stock transactions Form 4” the moment they hit EDGAR.
- Annual report 10-K sections on TORPEDO® platform costs are “C4 Therapeutics annual report 10-K simplified” for quick ratio checks.
- Proxy statements reveal “C4 Therapeutics proxy statement executive compensation” details without paging through exhibits.
Use our interactive dashboards to compare R&D spend quarter over quarter, track “C4 Therapeutics earnings report filing analysis,” and monitor “C4 Therapeutics Form 4 insider transactions real-time” before making allocation decisions. From “understanding C4 Therapeutics SEC documents with AI” to drilling into segment footnotes, Stock Titan delivers the full stack of filings insight so you can focus on valuing first-in-class degraders, not decoding legal prose.
C4 Therapeutics Director Owen Hughes received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting schedule: Full vesting upon earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting conditions require continued service as a board member, aligning the director's interests with long-term shareholder value. The transaction was executed under direct ownership, with attorney Jolie M. Siegel signing as the authorized representative.
C4 Therapeutics director Stephen Fawell received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting structure aligns with typical director compensation arrangements, requiring continued board service. The relatively low exercise price suggests the company's stock may have experienced recent price declines, as C4 Therapeutics focuses on targeted protein degradation for treating cancer and other diseases.
C4 Therapeutics director Kenneth Carl Anderson received a stock option grant on June 18, 2025. The derivative security details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The grant represents standard director compensation, with vesting contingent on continued board service. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025. This Form 4 disclosure complies with SEC requirements for reporting changes in beneficial ownership by company insiders.
C4 Therapeutics (NASDAQ:CCCC) filed a routine Form 4 on June 28, 2025, reporting that director Laura Bessen received a grant of 35,500 stock options on June 18, 2025 at an exercise price of $1.44 per share.
The options vest in full on the earlier of June 18, 2026 or the company’s next annual stockholder meeting, provided she remains on the board. No shares were sold, and the transaction reflects standard board compensation rather than an open-market trade. After the grant, Bessen directly holds 35,500 derivative securities.
C4 Therapeutics director Donna Roy Grogan received a stock option grant on June 18, 2025, as reported in a Form 4 filing. The derivative securities transaction details include:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a board member. This grant represents standard non-employee director compensation. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025.
C4 Therapeutics Director Steven L. Hoerter received a stock option grant on June 18, 2025 to purchase 35,500 shares of common stock at an exercise price of $1.44 per share.
Key details of the stock option:
- The option expires on June 17, 2035
- Vesting occurs at the earlier of June 18, 2026 or the next annual stockholders' meeting
- Vesting is contingent on continued Board service
- The grant was reported via Form 4 filing, indicating changes in beneficial ownership
This equity compensation aligns with standard director compensation practices and serves to align the director's interests with shareholders. The relatively low exercise price reflects the company's current market conditions.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
